{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:03:29Z","timestamp":1789067009044,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Scant data describe exocrine pancreatic insufficiency (EPI) secondary to immune checkpoint inhibitor (ICI) use. The goal of this study is to describe the incidence, risk factors, and clinical characteristics of patients with ICI-related EPI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>A single center, retrospective case-control study was performed of all ICI-treated patients at Memorial Sloan Kettering Cancer Center between January 2011 and July 2020. ICI-related EPI patients had steatorrhea with or without abdominal discomfort or weight loss, started pancrelipase after initiation of ICI, and demonstrated symptomatic improvement with pancrelipase. Controls were matched 2:1 by age, race, sex, cancer type, and year of ICI start.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 12\u2009905 ICI-treated patients, 23 patients developed ICI-related EPI and were matched to 46 controls. The incidence rate of EPI was 1.18 cases per 1000 person-years and the median onset of EPI was 390 days after the first dose of ICI. All 23 (100%) EPI cases had steatorrhea that improved with pancrelipase, 12 (52.2%) had weight loss, and 9 (39.1%) had abdominal discomfort; none had changes of chronic pancreatitis on imaging. Nine (39%) EPI patients had episodes of clinical acute pancreatitis preceding the onset of EPI, compared to 1 (2%) control (OR 18.0 (2.5-789.0), P &amp;lt; .001). Finally, the EPI group exhibited higher proportions of new or worsening hyperglycemia after ICI exposure compared with the control group (9 (39.1%) vs. 3 (6.5%), P &amp;lt; .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>ICI-related EPI is a rare but clinically significant event that should be considered in patients with late onset diarrhea after ICI treatment and often is associated with development of hyperglycemia and diabetes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad150","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:42:40Z","timestamp":1686184960000},"page":"1085-1093","source":"Crossref","is-referenced-by-count":21,"title":["Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5497-2476","authenticated-orcid":false,"given":"Deepika","family":"Satish","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Hsin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Flory","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gerdes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Postow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"},{"name":"Department of Medicine, Weill Cornell Medical College , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8245-9653","authenticated-orcid":false,"given":"David M","family":"Faleck","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"2","key":"2023122612565521100_CIT0001","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdw626","article-title":"Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy","volume":"28","author":"Hoadley","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"2023122612565521100_CIT0002","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/imt-2017-0126","article-title":"Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy","volume":"10","author":"Prasanna","year":"2018","journal-title":"Immunotherapy"},{"key":"2023122612565521100_CIT0003","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.08.024","article-title":"Diarrhoea during checkpoint blockade, not always colitis","volume":"87","author":"Koldenhof","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"2023122612565521100_CIT0004","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1158\/2326-6066.CIR-17-0659","article-title":"Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case\u2013control study","volume":"6","author":"Eshet","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2023122612565521100_CIT0005","doi-asserted-by":"crossref","first-page":"109250","DOI":"10.1016\/j.ejrad.2020.109250","article-title":"Imaging findings of immune checkpoint inhibitor associated pancreatitis","volume":"131","author":"Das","year":"2020","journal-title":"Eur J Radiol"},{"issue":"10","key":"2023122612565521100_CIT0006","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"issue":"2","key":"2023122612565521100_CIT0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","article-title":"Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way","volume":"123","author":"Cheung","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"2023122612565521100_CIT0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40425-019-0502-7","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J ImmunoTher Cancer"},{"issue":"4","key":"2023122612565521100_CIT0009","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pan.2019.04.015","article-title":"Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: a systematic review and meta-analysis","volume":"19","author":"George","year":"2019","journal-title":"Pancreatology"},{"issue":"12","key":"2023122612565521100_CIT0010","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased reporting of immune checkpoint inhibitor\u2013associated diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"issue":"8","key":"2023122612565521100_CIT0011","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"2","key":"2023122612565521100_CIT0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"2023122612565521100_CIT0013","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2023122612565521100_CIT0014","doi-asserted-by":"crossref","first-page":"620522","DOI":"10.3389\/fendo.2021.620522","article-title":"Coexistence of immune checkpoint inhibitor-induced autoimmune diabetes and pancreatitis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023122612565521100_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.02.017","article-title":"Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy\u2014a multicentre study of 90 patients from the German Dermatooncology Group","volume":"149","author":"Grimmelmann","year":"2021","journal-title":"Eur J Cancer"},{"key":"2023122612565521100_CIT0016","doi-asserted-by":"crossref","first-page":"627612","DOI":"10.3389\/fonc.2021.627612","article-title":"Immunotherapy-associated pancreatic adverse events: current understanding of their mechanism, diagnosis, and management","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/12\/1085\/54874865\/oyad150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/12\/1085\/54874865\/oyad150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T12:57:15Z","timestamp":1703595435000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/12\/1085\/7191692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,12,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad150","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,6,7]]}}}